𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tumor suppressor function of a dominant negative retinoic acid receptor mutant

✍ Scribed by David L. Crowe; Uyi E. Osaseri; Charles F. Shuler


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
163 KB
Volume
22
Category
Article
ISSN
0899-1987

No coin nor oath required. For personal study only.

✦ Synopsis


Mutations in receptors for the vitamin A metabolite retinoic acid (RAR) that repress retinoic acid (RA)-responsive gene expression have been identified and characterized. We previously reported an absence of target gene response to RA in all but one of a series of transformed human epithelial cell lines. To elucidate the mechanisms of this unresponsiveness, we created stable transfectants that expressed an RARα mutant (RARα403) previously shown to have dominant negative activity due to a C-terminal truncation. All clones exhibited repressed RA-responsive gene expression. These cells grew slowly and demonstrated greater growth inhibition by RA. Pretreatment of both control and experimental groups with RA enhanced epidermal growth factorinduced proliferation despite RA-dependent downregulation of epidermal growth factor receptor expression. In addition, clones expressing the mutant RARα were 60% less invasive in an in vitro assay. This reduced invasiveness correlated with decreased gelatinase activity in these cells. We showed for the first time that a dominant negative mutation in RARα can function as a tumor suppressor in transformed epithelial cells. Mol. Carcinog.


📜 SIMILAR VOLUMES


Retinoic acid receptor α dominant negati
✍ Atsushi Yanagitani; Sadako Yamada; Sakiko Yasui; Takashi Shimomura; Rie Murai; Y 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 529 KB

Although attention has focused on the chemopreventive action of retinoic acid (RA) in hepatocarcinogenesis, the functional role of RA in the liver has yet to be clarified. To explore the role of RA in the liver, we developed transgenic mice expressing RA receptor (RAR) alpha- dominant negative form

Induction of murine leukemia and lymphom
✍ Y. Alan Wang; Kate Shen; Yasumasa Ishida; Yaolin Wang; Akira Kakizuka; S.C. Broo 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 351 KB

Acute promyelocytic leukemia (APL) is invariably associated with chromosomal translocation to retinoic acid receptor a (RARa) locus. In a vast majority of cases, RARa translocates to and fuses with the promyelocytic leukemia (PML) gene. It was thought that the fusion protein PML-RARa acts as a doubl

Tumor suppressor function of Rab25 in tr
✍ Ji-Ming Cheng; Lisa Volk; Deepak Kumar Mummidavarapu Janaki; Sudhir Vyakaranam; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 879 KB

## Abstract Rab proteins are a group of ubiquitously expressed proteins that are responsible for intracellular transport of vesicles. Recent evidence has shown that certain Rab proteins are involved in the pathogenesis of cancer. We have recently shown that Rab25 is lost in a large fraction of brea

Negative regulation of mitogen-stimulate
✍ Cynthia A. Afshari; J. Carl Barrett 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 843 KB

## Abstract Immortal, nontumorigenic cell lines of Syrian hamster embryo (SHE) cells with different tumor‐suppressing activity were isolated. Subclones from the parental cells were isolated that either had retained (supB^+^) or lost (supB^−^) the ability to suppress tumorigenicity after hybridizati

Glial Cells Missing-2 (GCM2) transactiva
✍ Lucie Canaff; Xiang Zhou; Irina Mosesova; David E.C. Cole; Geoffrey N. Hendy 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 388 KB

Glial cells missing-2 (GCM2) is a transcription factor expressed in the parathyroid hormone (PTH)-secreting cells of the parathyroid gland and is essential for their development. Thus far, downstream targets of GCM2 have not been identified. Here, we show that both promoters (P1 and P2) of the calci

Transgenic overexpression of a dominant
✍ Anne-Odile Hueber; Susanne Bösser; Martin Zörnig 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 195 KB

## Abstract Activation of the so‐called death receptors, __e.g__., CD95/Fas/Apo‐1, is a potent stimulus to trigger apoptosis. Overexpression of the C‐terminal FADD deletion mutant FADD‐DN blocks death receptor–induced apoptosis, but despite this antiapoptotic activity, __lck FADD__‐__DN__ transgeni